GIM
HRTX icon

Glenmede Investment Management’s Heron Therapeutics HRTX Stock Holding History

Glenmede Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$133K Buy
105,326
+35,076
+50% +$55.6K ﹤0.01% 1321
2025
Q2 		$145K Buy
+70,250
New +$143K ﹤0.01% 1273

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Investment Management's HRTX Position: Q3 2025 in Review

Glenmede Investment Management increased its Heron Therapeutics (HRTX) stake by 50% in Q3 2025, buying an estimated $55.6K and bringing the position to 105,326 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Glenmede Investment Management first reported a position in HRTX in Q2 2025 and has held it in 2 quarters since. The position peaked at $145K in Q2 2025. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • Glenmede Investment Management held 105,326 shares of Heron Therapeutics worth $133K as of Q3 2025.
  • Glenmede Investment Management bought 35,076 Heron Therapeutics shares in Q3 2025, an estimated $55.6K.
  • Heron Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1321 holding.
  • Glenmede Investment Management first reported a position in Heron Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Heron Therapeutics position peaked at $145K in Q2 2025.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.